BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opinion on Drug Discovery 2018;14:81-9. [DOI: 10.1080/17460441.2019.1546691] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Adamo D, Pecoraro G, Coppola N, Calabria E, Aria M, Mignogna M. Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open-label randomized trial. Oral Dis 2021;27:1022-41. [PMID: 32790904 DOI: 10.1111/odi.13602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Ostuzzi G, Gastaldon C, Barbato A, D'Avanzo B, Tettamanti M, Monti I, Aguglia A, Aguglia E, Alessi MC, Amore M, Bartoli F, Biondi M, Bortolaso P, Callegari C, Carrà G, Caruso R, Cavallotti S, Crocamo C, D'Agostino A, De Fazio P, Di Natale C, Giusti L, Grassi L, Martinotti G, Nosé M, Papola D, Purgato M, Rodolico A, Roncone R, Tarsitani L, Turrini G, Zanini E, Amaddeo F, Ruggeri M, Barbui C. Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major depression. Study protocol of the VESPA study: a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial. Trials 2020;21:695. [PMID: 32746941 DOI: 10.1186/s13063-020-04460-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Guo X, McCutcheon RA, Pillinger T, Mizuno Y, Natesan S, Brown K, Howes O. The magnitude and heterogeneity of antidepressant response in depression: A meta-analysis of over 45,000 patients. J Affect Disord 2020;276:991-1000. [PMID: 32750615 DOI: 10.1016/j.jad.2020.07.102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Karrouri R, Hammani Z, Benjelloun R, Otheman Y. Major depressive disorder: Validated treatments and future challenges. World J Clin Cases 2021; 9(31): 9350-9367 [DOI: 10.12998/wjcc.v9.i31.9350] [Reference Citation Analysis]
5 Shalimova A, Babasieva V, Chubarev VN, Tarasov VV, Schiöth HB, Mwinyi J. Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics. Pharmacogenomics 2021;22:485-503. [PMID: 34018822 DOI: 10.2217/pgs-2020-0157] [Reference Citation Analysis]
6 Segura-Garcia C, Rania M, Carbone EA, de Filippis R, Aloi M, Caroleo M, Grasso G, Calabrò G, Fazia G, Staltari FA, Falvo A, Pugliese V, Gaetano R, Steardo L Jr, De Fazio P. Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression. Front Psychiatry 2021;12:635502. [PMID: 33815170 DOI: 10.3389/fpsyt.2021.635502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 McIntyre RS, Loft H, Christensen MC. Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder. Neuropsychiatr Dis Treat 2021;17:575-85. [PMID: 33654400 DOI: 10.2147/NDT.S296451] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yavi M, Henter ID, Park LT, Zarate C. Key considerations in the pharmacological management of treatment-resistant depression. Expert Opin Pharmacother 2021;:1-11. [PMID: 34252320 DOI: 10.1080/14656566.2021.1951225] [Reference Citation Analysis]
9 Talmon M, Chaudhari RD, Suryavanshi H, Chowdhury N, Quaregna M, Pin A, Bagchi A, Biswas G, Fresu LG. Design, synthesis and biological evaluation of vortioxetine derivatives as new COX-1/2 inhibitors in human monocytes. Bioorg Med Chem 2020;28:115760. [PMID: 32992247 DOI: 10.1016/j.bmc.2020.115760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Hrnjadovic A, Friedmann J, Barhebreus S, Allen PJ, Kocsis B. Effect of a 5-HT7 Receptor Antagonist on Reversal Learning in the Rat Attentional Set-Shifting Test. ACS Chem Neurosci 2021;12:42-8. [PMID: 33337152 DOI: 10.1021/acschemneuro.0c00554] [Reference Citation Analysis]
11 Christensen MC, Fagiolini A, Florea I, Loft H, Cuomo A, Goodwin GM. Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting. J Affect Disord 2021;294:924-31. [PMID: 34378539 DOI: 10.1016/j.jad.2021.07.099] [Reference Citation Analysis]
12 Ye X, Wang D, Zhu H, Wang D, Li J, Tang Y, Wu J. Gut Microbiota Changes in Patients With Major Depressive Disorder Treated With Vortioxetine. Front Psychiatry 2021;12:641491. [PMID: 34025474 DOI: 10.3389/fpsyt.2021.641491] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 De Berardis D, Fornaro M, Anastasia A, Vellante F, Olivieri L, Rapini G, Serroni N, Orsolini L, Valchera A, Carano A, Tomasetti C, Ventriglio A, Bustini M, Pompili M, Serafini G, Perna G, Iasevoli F, Martinotti G, Di Giannantonio M. Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study. Braz J Psychiatry 2020;42:317-21. [PMID: 32159712 DOI: 10.1590/1516-4446-2019-0690] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
14 Liu X, Sun YX, Zhang CC, Zhang XQ, Zhang Y, Wang T, Ma YN, Wang H, Su YA, Li JT, Si TM. Vortioxetine attenuates the effects of early-life stress on depression-like behaviors and monoamine transporters in female mice. Neuropharmacology 2021;186:108468. [PMID: 33485943 DOI: 10.1016/j.neuropharm.2021.108468] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Sanches M, Quevedo J, Soares JC. New agents and perspectives in the pharmacological treatment of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2021;106:110157. [PMID: 33159975 DOI: 10.1016/j.pnpbp.2020.110157] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Sałat K, Furgała-Wojas A. Serotonergic Neurotransmission System Modulator, Vortioxetine, and Dopaminergic D2/D3 Receptor Agonist, Ropinirole, Attenuate Fibromyalgia-Like Symptoms in Mice. Molecules 2021;26:2398. [PMID: 33924258 DOI: 10.3390/molecules26082398] [Reference Citation Analysis]
17 Dvojkovic A, Nikolac Perkovic M, Sagud M, Nedic Erjavec G, Mihaljevic Peles A, Svob Strac D, Vuksan Cusa B, Tudor L, Kusevic Z, Konjevod M, Zivkovic M, Jevtovic S, Pivac N. Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2021;105:110016. [PMID: 32534176 DOI: 10.1016/j.pnpbp.2020.110016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
18 Chokka P, Tvistholm AH, Bougie J, Clerzius G, Ettrup A. Improvements in Workplace Productivity in Working Patients With Major Depressive Disorder: Results From the AtWoRC Study. J Occup Environ Med 2020;62:e94-e101. [PMID: 31895735 DOI: 10.1097/JOM.0000000000001805] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Papp M, Gruca P, Faron-górecka A, Kusmider M, Willner P. Genomic Screening of Wistar and Wistar-Kyoto Rats Exposed to Chronic Mild Stress and Deep Brain Stimulation of Prefrontal Cortex. Neuroscience 2019;423:66-75. [DOI: 10.1016/j.neuroscience.2019.10.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]